Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C106254
http://purl.obolibrary.org/obo/NCIT_C106254
|
|---|---|
| Preferred Name | Tovorafenib |
| Definitions |
An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival. |
|---|---|
| prefLabel | Tovorafenib
|
| label | Tovorafenib
|
| NCI_META_CUI | CL433881
|
| PDQ_Closed_Trial_Search_ID | 710688
|
| code | C106254
|
| Has_Target | |
| prefixIRI | NCIT:C106254
|
| in_subset |
See more
See less
|
| Display_Name | Tovorafenib
|
| Preferred_Name | Tovorafenib
|
| FDA_UNII_Code | ZN90E4027M
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | pan-RAF Kinase Inhibitor TAK-580
|
| CAS_Registry | 1096708-71-2
|
| NCI_Drug_Dictionary_ID | 710688
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 710688
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |